Current Market Access to Avsola, Inflectra and Remicade

While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.

NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/12/21.

AIS Health Staff

AIS Health Staff

Related Posts

charts-on-tablet
June 1

Report Examines Utilization, Spending Growth of U.S. Health Care Services

Read More
businessman-analyzing-company-report-working-with-digital-augmented-reality-graphics
June 1

MMIT Payer Portrait: Blue Cross Blue Shield of Michigan

Read More
pills-in-hand
June 1

As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today